PDM-631

• Description :

  PDM-631 is a selective and orally active PDE2A inhibitor with blood-brain barrier penetration. PDM-631 exhibits potent inhibitory activity against human and rat recombinant PDE2A with IC50 values of 1.5 nM and 4.2 nM, respectively. PDM-631 increases cGMP levels in the rat cerebral cortex. PDM-631 can be used for the study of schizophrenia and neurodegenerative disorders[1].

• UNSPSC :

  12352005

• Target :

  Phosphodiesterase (PDE)

• Related Pathways :

  Metabolic Enzyme/Protease

• Field of Research :

  Neurological Disease

• Smiles :

  FC(F)(F)OC(C=C1)=CC=C1C[C@@H](N2C3=C(C(N=C(N3)C)=O)C(C4CC4)=N2)C

• Molecular Formula :

  C19H19F3N4O2

• Molecular Weight :

  392.37

• References & Citations :

  [1]Maehara S, et al. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631. Eur J Pharmacol. 2017 Sep 15;811:110-116.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PDE2

• CAS Number :

  [2095312-08-4]